Cellectis S.A. (EPA:ALCLS)
France · Delayed Price · Currency is EUR | Market Cap | 246.63M |
| Revenue (ttm) | 54.02M |
| Net Income (ttm) | -50.24M |
| Shares Out | 72.33M |
| EPS (ttm) | -0.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 859,305 |
| Average Volume | 1,086,310 |
| Open | 3.535 |
| Previous Close | 3.410 |
| Day's Range | 3.000 - 3.630 |
| 52-Week Range | 1.010 - 4.840 |
| Beta | 3.07 |
| RSI | 53.76 |
| Earnings Date | Nov 3, 2025 |
About Cellectis
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric an... [Read more]
Financial Performance
In 2024, Cellectis's revenue was $49.22 million, an increase of 435.37% compared to the previous year's $9.19 million. Losses were -$36.76 million, -63.62% less than in 2023.
Financial numbers in USD Financial StatementsNews
CLLS: Analyst Raises Price Target Significantly for Cellectis | CLLS Stock News
CLLS: Analyst Raises Price Target Significantly for Cellectis | CLLS Stock News
Cellectis' R&D Day Highlights Lasme-cel's Potential to Address Significant Unmet Need for Patients with r/r B-ALL
○ Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9)
Top 2 Health Care Stocks That May Keep You Up At Night This Month
As of Oct. 16, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers
NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to deve...
Allogene licensor Cellectis faces patent lawsuit in the U.S.
Allogene (ALLO) stock is down as its licensor Cellectis (CLLS) faces a patent infringement case in the U.S. over a gene editing technology. Read more here.
Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...
Top 5 Biotech Stocks With Strong Momentum
Among biotechnology stocks, several names have hovered around the top momentum percentile this week, signaling robust bullish activity and potential for short-term gains. Top 5 Biotechnology Firms On ...
Cellectis S.A. (CLLS) Q2 2025 Earnings Call Transcript
Cellectis GAAP EPS of -$0.24 misses by $0.03, revenue of $16M beats by $4.36M
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to deve...
Earnings Scheduled For August 4, 2025
Companies Reporting Before The Bell • Kosmos Energy (NYSE: KOS) is likely to report quarterly loss at $0.07 per share on revenue of $415.09 million. • Sohu.com (NASDAQ: SOHU) is likely to report ear...
Cellectis Q2 2025 Earnings Preview
Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to devel...
Cellectis files $200M mixed shelf offering
Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025
NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving c...
Cellectis' Annual Shareholders General Meeting to be Held on June 26, 2025
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to devel...
Cellectis: Partnerships And Promised Data In 2025 Continue To Justify The Buy
Discover Cellectis SA's innovative CAR T-cell therapies targeting heme malignancies & upcoming 2025 catalysts.
Cellectis Non-GAAP EPS of -$0.17, revenue of $12M misses by $1.83M
Cellectis Reports Financial Results for the First Quarter 2025
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to devel...
Cellectis Q1 2025 Earnings Preview
Cellectis to Report First Quarter Financial Results on May 12, 2025
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develo...
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to dev...
Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript
Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Shares of Rubrik, Inc. (NYSE: RBRK) rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued first-quarter guidance above...